Literature DB >> 18545220

Repeat administration of proteins to the eye with a single intraocular injection of an adenovirus vector.

Duncan McVey1, Melissa M Hamilton, Chi Hsu, C Richter King, Douglas E Brough, Lisa L Wei.   

Abstract

Delivery of therapeutic proteins, such as antiangiogenic proteins, to the eye is a demonstrated method for the control of age-related macular degeneration (AMD). However, one of the key limitations is the requirement for frequent and repeated intraocular injections. In this article, we demonstrate that repeated protein production in the eye can be stimulated from the cytomegalovirus (CMV) promoter without repeat intraocular injections using a small molecule, all-trans retinoic acid (ATRA). ATRA by systemic delivery can stimulate protein production multiple times in the eye. Administration of ATRA resulted in stimulation of gene expression to relevant levels that block abnormal blood vessel growth in an experimental animal model for AMD. These data support the principles of this technological discovery to therapeutic applications for chronic ocular diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545220     DOI: 10.1038/mt.2008.124

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  4 in total

1.  Agarose surface coating influences intracellular accumulation and enhances payload stability of a nano-delivery system.

Authors:  Enrica De Rosa; Ciro Chiappini; Dongmei Fan; Xuewu Liu; Mauro Ferrari; Ennio Tasciotti
Journal:  Pharm Res       Date:  2011-05-24       Impact factor: 4.200

2.  Multiple treatment cycles of liposome-encapsulated adenoviral RIP-TK gene therapy effectively ablate human pancreatic cancer cells in SCID mice.

Authors:  Shi-He Liu; Nancy Smyth-Templeton; Alan R Davis; Elizabeth A Davis; Nikiforos Ballian; Min Li; Hao Liu; William Fisher; F Charles Brunicardi
Journal:  Surgery       Date:  2011-02-05       Impact factor: 3.982

3.  Optimizing atoh1-induced vestibular hair cell regeneration.

Authors:  Hinrich Staecker; Christina Schlecker; Shannon Kraft; Mark Praetorius; Chi Hsu; Douglas E Brough
Journal:  Laryngoscope       Date:  2014-06-17       Impact factor: 3.325

4.  Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.

Authors:  Melissa M Hamilton; Gordon A Byrnes; Jason G Gall; Douglas E Brough; C Richter King; Lisa L Wei
Journal:  Mol Vis       Date:  2008-12-30       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.